Fluconazole Suspension for Oropharyngeal Candidiasis Unresponsive to Tablets (1997)

Letters15 February 1997Fluconazole Suspension for Oropharyngeal Candidiasis Unresponsive to TabletsMarcelo D. Martins, MD and John H. Rex, MDMarcelo D. Martins, MDUniversity of Texas Medical School, Houston, TX 77030 and John H. Rex, MDUniversity of Texas Medical School, Houston, TX 77030Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-4-199702150-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:While receiving the intermittent or continuous therapy that is required to treat relapses of oropharyngeal candidiasis, as many as 5% to 10% of patients with advanced human immunodeficiency virus (HIV) infection develop an infection that is clinically or microbiologically resistant to 100 to 200 mg of fluconazole per day [1]. Fluconazole is now available in a suspension of 10 or 40 mg/mL, and we hypothesized that the high salivary levels that are associated with use in a swish-and-swallow format [2] might overcome resistance in some patients.Patient 1 was a 43-year-old man who had a recent CD4+ ...References1. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995; 39:1-8. Google Scholar2. Laufen H, Yeates RA, Zimmermann T, de los Reyes C. Pharmacokinetic optimization of the treatment of oral candidiasis with fluconazole: studies with a suspension. Drug Exp Clin Res. 1995; 21:23-8. Google Scholar3. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: proposed standard. M27-T. Wayne, PA: National Committee for Clinical Laboratory Standards; 1995. Google Scholar Author, Article, and Disclosure InformationAuthors: Marcelo D. Martins, MD; John H. Rex, MDAffiliations: University of Texas Medical School, Houston, TX 77030 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Role of Resistance in Candida Infections: Epidemiology and TreatmentESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDSCandidiasisMucocutaneous and Deeply Invasive CandidiasisComparison of efficacy of fluconazole mouthrinse and clotrimazole mouthpaint in the treatment of oral candidiasisTreatment strategies for oropharyngeal candidiasisThe Role of Resistance in Candida Infections: Epidemiology and TreatmentFungal Opportunistic Infections in HIV DiseaseGuidelines for Treatment of CandidiasisAntifungal therapy - state of the art at the beginning of the 21st centuryMucosal candidiasisEfficacy of Caspofungin in the Treatment of Esophageal Candidiasis Resistant to FluconazoleA comparative study of the efficacy and safety of fluconazole oral suspension and amphotericin B oral suspension in cancer patients with mucositisDNA fingerprinting of serial Candida albicans isolates obtained during itraconazole prophylaxis in patients with AIDSPractice Guidelines for the Treatment of CandidiasisClinical management of selected oral fungal and viral infections during HIV-diseaseCurrent and Emerging Azole Antifungal AgentsOptions for the Management of Mucosal Candidiasis in Patients with AIDS and HIV InfectionAntifungal Agents. Part II. The Azoles 15 February 1997Volume 126, Issue 4Page: 332-333KeywordsAttentionCandidaCandidiasisHIVHIV infectionsImmune responseInfectious diseasesOpportunistic infectionsOropharynx ePublished: 15 August 2000 Issue Published: 15 February 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...